Seagen announces last patient enrolled in phase 2 mountaineer trial evaluating tukysa® (tucatinib) regimen in her2-positive metastatic colorectal cancer

Bothell, wash.--(business wire)--seagen announces last patient enrolled in phase 2 mountaineer trial evaluating tukysa® regimen in her2-positive metastatic colorectal cancer

SGEN Ratings Summary

SGEN Quant Ranking